The T wave as a marker of dispersion of ventricular repolarization in premature infants before and while on treatment with the I(Kr) channel blocker cisapride

Cardiol Young. 2002 Jan;12(1):32-6. doi: 10.1017/s1047951102000069.

Abstract

Aims: Measurement of electrocardiographic intervals to assess dispersion in ventricular repolarization may be helpful in the assessment of the risk of ventricular arrhythmia. We measured QTc, QT dispersion, and T wave intervals in premature infants before and while on treatment with the I(Kr) blocker cisapride as markers for dispersion in ventricular repolarization.

Methods and results: We enrolled 15 non-ventilated premature infants with a mean gestational age of 30.5 weeks, ranging from 26.5 to 33.5 weeks, and mean postnatal age of 24 days, with a range from 5 to 51 days. A digital 12 lead electrocardiogram was recorded prior to and 3 days after administering cisapride at a dose of 0.8 mg/kg/day. Serum electrolytes were simultaneously measured. Electrocardiographic measurements before and after included: QT, QTc Bazett, QT dispersion, R-R, T wave interval peak to end, T wave interval peak to end/onset Q to T wave peak, T wave axis, T wave maximum voltage and QRS-T angle. A paired t test and analysis of variance was used to compare the variables before and during treatment. The QTc, T wave interval peak to end and the ratio T wave interval peak to end/onset Q to T peak increased significantly following treatment with cisapride. Results expressed as before and during treatment were for QTc: 429 (65) ms versus 454 (29) ms p < 0.02; for T wave interval peak to end: 65 (11) ms versus 103 (24) p <0.01, for the ratio T wave interval peak to end/onset Q to T peak: 0.32 (0.06) versus 0.55 (0.16) p < 0.001. Treatment with the I(Kr) blocker did not significantly alter the QT dispersion, T wave voltage, angle or QRS-T angle.

Conclusion: The interval from the peak to the end of the T wave and the ratio of this value to the onset Q to T peak interval, represents regional dispersion of repolarization across the ventricular wall. This is a potentially useful clinical index in the assessment of arrhythmic risk in premature infants being treated by blockade of the I(Kr) channels.

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Belgium
  • Cation Transport Proteins*
  • Cisapride / administration & dosage
  • Cisapride / antagonists & inhibitors*
  • DNA-Binding Proteins*
  • ERG1 Potassium Channel
  • Electrocardiography*
  • Ether-A-Go-Go Potassium Channels
  • Humans
  • Infant
  • Infant Welfare
  • Infant, Newborn
  • Infant, Premature*
  • Long QT Syndrome / complications
  • Long QT Syndrome / drug therapy
  • Long QT Syndrome / epidemiology
  • Potassium Channel Blockers*
  • Potassium Channels / administration & dosage
  • Potassium Channels, Voltage-Gated*
  • Risk Factors
  • Trans-Activators*
  • Transcriptional Regulator ERG
  • Ventricular Premature Complexes / epidemiology
  • Ventricular Premature Complexes / etiology

Substances

  • Cation Transport Proteins
  • DNA-Binding Proteins
  • ERG protein, human
  • ERG1 Potassium Channel
  • Ether-A-Go-Go Potassium Channels
  • KCNH6 protein, human
  • Potassium Channel Blockers
  • Potassium Channels
  • Potassium Channels, Voltage-Gated
  • Trans-Activators
  • Transcriptional Regulator ERG
  • Cisapride